The global demand for Vesicoureteral Reflux Market is presumed to reach the market size of nearly USD 3.67 MN by 2030 from USD 2.19 MN in 2022 with a CAGR of 6.7% under the study period 2023 - 2030.
Vesicoureteral reflux occurs when urine flows backwards from the bladder into the ureters/kidneys. In a normal state, urine flows unidirectionally from the kidneys to the bladder via the ureters. The ureterovesical valve, a one-way flap valve found at the vesicoureteral junction, prevents backflow. Primary VUR and secondary VUR are the two forms of VUR. Primary VUR is caused by the ureter's length being insufficient compared to its diameter, resulting in a diminished valvular mechanism's ability to control urine flow. A congenital anomaly causes primary VUR. Secondary VUR is induced by increasing bladder pressures associated with blockage, which might be anatomical or functional, overpowering the ureters' valvular mechanism. The pressure may cause the ureterovesical valve to distort, necessitating surgical intervention to repair the abnormality. A strong and persistent urge to urinate, often accompanied by a burning feeling when urinating, a high frequency of urinating in small amounts, blood in the urine, often with a strong odor, fever, abdominal pain are the indications and symptoms. VUR can lead to a urinary tract infection (UTI) due to urine backflow, which raises the risk of disease.
Market Dynamics
Increased awareness and the availability of sophisticated biocompatible goods such as dextranomer and hyaluronic acid gels, which are injected to treat VUR, are projected to boost the market. VUR Injection is a step forward from current surgery treatments because it is less intrusive and takes less time in the hospital. Surgical robots, which are more precise and inflict minor trauma, is expected to supplement the market growth. Overall, rising per capita income and a growing acceptance of surgeries worldwide will further drive the market. On the other hand, VUR diagnostic and therapeutic problems and discomfort, the intrusive nature of open surgery and infections might stifle the market development.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of vesicoureteral reflux. The growth and trends of vesicoureteral reflux industry provide a holistic approach to this study.
Market Segmentation
This section of the vesicoureteral reflux market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Type
- Primary Vesicoureteral Reflux
- Secondary Vesicoureteral Reflux
By Drug
- Aminoglycosides
- Quinolones
- Beta-Lactam
- Azoles
- Others
By Treatment
- Medication
- Surgery
- Others
By Diagnosis
- Urinalysis
- Ultrasound
- X-Ray
- Cystography
- Nuclear Scan
- Others
By End-Users
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Regional Analysis
This section covers the regional outlook, which accentuates current and future demand for the Vesicoureteral Reflux market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Global Vesicoureteral Reflux Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Vesicoureteral Reflux market include Pfizer Inc., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Salix Pharmaceuticals, Cook, Medtronic, Johnson & Johnson Private Limited, Fresenius SE & Co. KGaA, Abbott, GENERAL ELECTRIC COMPANY, Boston Scientific Corporation, Zimmer Biomet, Teva Pharmaceutical Industries Ltd., Sanofi, Sun Pharmaceutical Industries Ltd., Merck Sharp & Dohme Corp. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.